Analysis of Patients with Focal Epilepsy and Drug-Resistant Epilepsy in Italy: Evaluation of Their Characteristics, Therapeutic Pathway and the Consumption of Healthcare Resources
Valentina Perrone,1 Chiara Veronesi,1 Melania Dovizio,1 Domenica Daniela Ancona,2 Margherita Andretta,3 Fausto Bartolini,4 Arturo Cavaliere,5 Alessandro Chinellato,6 Andrea Ciaccia,7 Mariarosaria Cillo,8 Adele De Francesco,9 Nicola Enieri,6 Fulvio Ferrante,10 Simona Gentile,11 Cataldo Procacci,2 Lor...
Saved in:
Main Authors: | Perrone V (Author), Veronesi C (Author), Dovizio M (Author), Ancona DD (Author), Andretta M (Author), Bartolini F (Author), Cavaliere A (Author), Chinellato A (Author), Ciaccia A (Author), Cillo M (Author), De Francesco A (Author), Enieri N (Author), Ferrante F (Author), Gentile S (Author), Procacci C (Author), Ubertazzo L (Author), Vercellone A (Author), Lucatelli D (Author), Procaccini M (Author), Degli Esposti L (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical and economic burden of respiratory syncytial virus in children aged 0-5 years in Italy
by: Melania Dovizio, et al.
Published: (2024) -
Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy
by: Degli Esposti L, et al.
Published: (2022) -
Evaluation of the Therapeutic Pattern and Pharmaco-Utilization in Hypercholesterolemic Patients Treated with Statins: A Retrospective Study on Italian Real-World Data
by: Perrone V, et al.
Published: (2022) -
Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy
by: Degli Esposti L, et al.
Published: (2017) -
Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
by: Fagiuoli S, et al.
Published: (2023)